Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
21 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pharminox Limited - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Pharminox Limited - Product Pipeline Review - 2015', provides an overview of the Pharminox Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Pharminox Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Pharminox Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Pharminox Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Pharminox Limited's pipeline products Reasons to buy - Evaluate Pharminox Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Pharminox Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Pharminox Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Pharminox Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharminox Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Pharminox Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Pharminox Limited Snapshot 4 Pharminox Limited Overview 4 Key Information 4 Key Facts 4 Pharminox Limited - Research and Development Overview 5 Key Therapeutic Areas 5 Pharminox Limited - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pharminox Limited - Pipeline Products Glance 9 Pharminox Limited - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Discovery Products/Combination Treatment Modalities 10 Pharminox Limited - Drug Profiles 11 PMX-500 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 PMX-700 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 PMX-900 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Pharminox Limited - Pipeline Analysis 14 Pharminox Limited - Pipeline Products by Target 14 Pharminox Limited - Pipeline Products by Molecule Type 15 Pharminox Limited - Pipeline Products by Mechanism of Action 16 Pharminox Limited - Recent Pipeline Updates 17 Pharminox Limited - Dormant Projects 18 Pharminox Limited - Locations And Subsidiaries 19 Head Office 19 Appendix 20 Methodology 20 Coverage 20 Secondary Research 20 Primary Research 20 Expert Panel Validation 20 Contact Us 20 Disclaimer 21
List of Tables
Pharminox Limited, Key Information 4 Pharminox Limited, Key Facts 4 Pharminox Limited - Pipeline by Indication, 2015 6 Pharminox Limited - Pipeline by Stage of Development, 2015 7 Pharminox Limited - Monotherapy Products in Pipeline, 2015 8 Pharminox Limited - Preclinical, 2015 9 Pharminox Limited - Discovery, 2015 10 Pharminox Limited - Pipeline by Target, 2015 14 Pharminox Limited - Pipeline by Molecule Type, 2015 15 Pharminox Limited - Pipeline Products by Mechanism of Action, 2015 16 Pharminox Limited - Recent Pipeline Updates, 2015 17 Pharminox Limited - Dormant Developmental Projects,2015 18
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.